Committees’ consolidated opinions available on applications for authorisation
The consolidated opinions of the Committees for Risk Assessment (RAC) and Socio-economic Analysis (SEAC) are available for applications of authorisation for uses of 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated by Vetter Pharma-Fertigung GmbH & Co. KG and by Novo Nordisk A/S.